Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Botensilimab - Agenus

Next Previous
Drug Profile

Botensilimab - Agenus

Alternative Names: AGEN-1181; Anti-CTLA-4 Monoclonal Antibody AGEN1181; BOT - Agenus; Fc-enhanced CTLA-4 antibody

Latest Information Update: 01 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Agenus
  • Developer Agenus; Immune Oncology Research Institute
  • Class Antibodies; Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Adenocarcinoma
  • Phase II/III Solid tumours
  • Phase II Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Rectal cancer; Renal cell carcinoma
  • Clinical Phase Unknown Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Soft tissue sarcoma

Most Recent Events

  • 21 May 2026 Efficacy and adverse events data from a phase II trial in Malignant melanoma released by Agenus
  • 19 May 2026 City of Hope Medical Center plans a phase II trial for Colorectal cancer (Neoadjuvant therapy, Late-stage disease, Combination therapy) in USA (IV) in December 2026 (NCT07595874)
  • 27 Apr 2026 Agenus plans a phase II trial for Colorectal cancer (Combination therapy) in May 2026 (IV) (NCT07551596)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top